Aggressive cut
Fat loss approached from burn-more rather than eat-less.
The idea
The fat-loss framing applies in full: a calorie deficit does the work, and everything here is an addition to it. Where the standard fat-loss stack is incretin-led and appetite-first, this one drops the appetite axis entirely and adds thermogenesis. That is a real difference — and a harder one, because appetite suppression makes a deficit sustainable in a way that burning more does not.
What's in it
| Compound | Role in this stack | Evidence |
|---|---|---|
| Cardarine (GW501516) | PPAR-delta agonist pushing fat as fuel; reads as endurance during training. | Investigational; development ended after dose-dependent rodent carcinogenicity |
| ATX-304 | Direct pan-AMPK activator; raises both cellular energy supply and demand. | Early clinical |
| Mirabegron | Beta-3 adrenergic agonist activating brown adipose tissue thermogenesis. | Approved drug (bladder); off-label use here |
| SANA (MVD1) | Creatine-dependent adipose thermogenesis: a futile creatine cycle that burns ATP and releases heat, independent of UCP1 and appetite. | Investigational; preclinical + short Phase 1 |
| L-Carnitine | Moves long-chain fatty acids into the mitochondrion; raises muscle carnitine poorly in people who are not deficient. | Supplement; weakest link |
Overlap & conflict
Three of the five push the same fuel-selection axis at once — PPAR-delta, AMPK, and carnitine transport all change what is burned. That is redundancy, not synergy, and carnitine is the reasonable one to drop. The genuine non-overlap is mirabegron: it changes how much is burned, not what is burned. No adverse pair interactions flagged at the class level.
What we don't know
Burn-more without a deficit produces very little — the deficit is the intervention and these are additions. Whether the thermogenic additions produce meaningful extra loss in humans, beyond the deficit itself, is not established for this combination.
Reality check
Read 'aggressive' as a warning, not a promise. Pushing expenditure while a deficit is already running is how lean mass is lost quickly, and nothing here protects against that — training and protein do. Mirabegron's beta-3 selectivity is not absolute: elevated heart rate and blood pressure are documented, it inhibits CYP2D6, and those effects matter most in exactly the population likely to stack it with stimulants. Cardarine's rodent carcinogenicity is what ended its development; the absence of a human case report does not erase it.
Stoic Cookie verdict
The riskiest stack of the five, and the one where the headline should stay on the deficit. As an analysis of burn-more pharmacology it is interesting; as a plan it stacks a discontinued carcinogenicity case, an off-label cardiovascular-active prescription drug, and two investigational thermogenics on top of an already demanding deficit.
Roster inspired by Scientific Sean's aggressive cut stack, rewritten in Stoic Cookie format. His page is the original; this page is the concise, evidence-labeled version.